MARY BUSCH: Open Payments
NPI 1821787300 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$485 in 27 payments from 11 companies in 2025. Trend: 2023 $568 · 2024 $990 · 2025 $485
Food & beverage: $485
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $155 |
| Lilly USA, LLC | 4 | $61 |
| Astellas Pharma US Inc | 3 | $58 |
| Amgen Inc. | 3 | $44 |
| Abbott Laboratories | 2 | $38 |
| Gilead Sciences, Inc. | 2 | $37 |
| ABBVIE INC. | 1 | $26 |
| Eisai Inc. | 1 | $17 |
| PFIZER INC. | 1 | $17 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $16 |
Products named: AIRSUPRA, Veozah, FARXIGA, FREESTYLE LIBRE 3, MOUNJARO, KISUNLA, OTEZLA, UBRELVY.
Industry payments across AZ — which companies pay providers there.
